Quest Diagnostics Gestion
Gestion contrôle des critères 4/4
Le PDG Quest Diagnostics est Jim Davis, nommé en Nov2022, a un mandat de 3.67 ans. La rémunération annuelle totale est $ 15.50M, composée du salaire de 8.1% et des bonus 91.9%, y compris les actions et options de la société. détient directement 0.12% des actions de la société, d'une valeur de $ 30.17M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 4 ans et 6.3 ans.
Informations clés
Jim Davis
Directeur général
US$15.5m
Rémunération totale
| Pourcentage du salaire du PDG | 8.07% |
| Durée du mandat du directeur général | 3.7yrs |
| Propriété du PDG | 0.1% |
| Durée moyenne d'occupation des postes de direction | 4yrs |
| Durée moyenne du mandat des membres du conseil d'administration | 6.3yrs |
Mises à jour récentes de la gestion
Recent updates
Article d’analyse • Jul 26
Earnings Beat: Quest Diagnostics Incorporated Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Quest Diagnostics Incorporated ( NYSE:DGX ) defied analyst predictions to release its second-quarter results, which...
Mise à jour du récit • Jul 25
DGX: Advanced Diagnostics And AI Progress Will Support Balanced Risk Reward Profile
The analyst price target for Quest Diagnostics has been raised from $223.44 to $239.38, reflecting updated views that recent Q2 beats, higher guidance, and ongoing organic growth can support slightly stronger profit margins while keeping a similar P/E framework in place. Analyst Commentary Recent research on Quest Diagnostics points to a generally constructive stance, with most price targets moving higher after the Q2 report.Seeking Alpha • Jul 24
Quest Diagnostics Upgrades EPS Outlook For 2026 After Outperforming Q2 Results
Summary Quest Diagnostics earns a reiterated buy rating after Q2 earnings beat, upgraded FY guidance, and continued market momentum. DGX benefits from strong macro demand for specialized diagnostic testing, peer-leading ROE, and resilient top-line growth (+10.2% YoY). Upward earnings revisions, robust dividend growth, and investment-grade credit ratings support the bull case, though cost pressures and payor risk warrant monitoring. Valuation shows some opportunity, but total return forecast falls short of hurdle rate; sector-specific regulatory risks remain a challenge. Read the full article on Seeking AlphaArticle d’analyse • Jun 21
Quest Diagnostics (DGX) Stock Could Be 12.7% Below Fair Value on Testing Growth Narrative
Recent Share Performance and Business Scale Quest Diagnostics (DGX) has seen its stock decline about 1.4% over the past day and roughly 4% over the past week, while returns over the past month and past 3 months are close to flat. Despite these short term moves, the company operates at considerable scale, with revenue of about $11.3b and net income of roughly $1.0b, and a market value near $21.6b based on the latest figures. See our latest analysis for Quest Diagnostics. At a share price of...Mise à jour du récit • Jun 18
DGX: Advanced Diagnostics And AI Execution Will Support Safe Haven Appeal
Analysts have nudged their blended price targets on Quest Diagnostics higher, with a series of $5 to $20 upward revisions from multiple firms helping to justify only marginal tweaks to the model inputs and leaving the fair value estimate essentially unchanged at about $223.44 per share. Analyst Commentary Recent research on Quest Diagnostics clusters around a constructive stance, with several firms lifting price targets in increments of US$5 to US$20 while leaving underlying estimates and the blended fair value near US$223.44 per share.Mise à jour du récit • Jun 04
DGX: Raised 2026 Guidance And Execution Strength Will Sustain Safe Haven Appeal
Quest Diagnostics' analyst price target nudged up by about $0.19 to roughly $223.44 as analysts fine-tuned assumptions around the discount rate, revenue growth, profit margins, and future P/E, following a series of recent target increases across major research firms. Analyst Commentary Recent research has converged around higher price targets for Quest Diagnostics, with several firms adjusting their models and one firm previously cutting its target while keeping a more tactical positive stance.Mise à jour du récit • May 13
DGX: Refreshed 2026 Outlook And Margin Assumptions Will Sustain Safe Haven Appeal
Quest Diagnostics' analyst price target has been revised to $223.25 from $218.19 as analysts factor in recent target increases across the Street and updated assumptions around discount rate, profit margins and future P/E multiples. Analyst Commentary Recent Street research around Quest Diagnostics has centered on refreshed valuation work and price target changes, with several firms adjusting their numbers based on updated assumptions for discount rates, profit margins and future P/E multiples.Mise à jour du récit • Apr 20
DGX: Organic Guidance And Capital Returns Will Sustain Safe Haven Appeal
Analyst price targets for Quest Diagnostics have been adjusted slightly lower to $218.19 from $218.50, as analysts factor in updated views on revenue growth, profit margins, and long term P/E assumptions following a series of recent target changes across the coverage universe. Analyst Commentary Recent research updates point to a mixed but generally constructive stance on Quest Diagnostics, with multiple target changes and one fresh list inclusion helping to frame how analysts are thinking about valuation, execution, and growth risk.Mise à jour du récit • Apr 05
DGX: Organic Guidance And Capital Returns Will Support Safe Haven Profile
Analysts have raised their price targets on Quest Diagnostics by between $5 and $30, largely pointing to recently issued organic revenue growth guidance and viewing the broader diagnostic lab space as a relative safe haven within healthcare services. Analyst Commentary Recent Street research around Quest Diagnostics and its closest peer highlights a constructive setup for the broader diagnostic lab group, with price target moves on Quest generally framed against views that the sector can act as a relative safe haven within healthcare services.Mise à jour du récit • Mar 22
DGX: Premium Multiple And Capital Returns Look Supported By Organic Revenue Guidance
Analysts have raised their price targets on Quest Diagnostics by a range of $5 to $30, citing the company’s recent organic revenue growth guidance and viewing the diagnostic testing space as a relative safe haven within healthcare services. Analyst Commentary Recent research on Quest Diagnostics highlights a cluster of higher price targets and an upgrade, with many investors treating large diagnostic labs as a relatively defensive corner of healthcare services.Mise à jour du récit • Mar 07
DGX: Fair Outlook As Premium Multiple And Capital Returns Shape Future Earnings
Analysts raised their price target on Quest Diagnostics by about $1 to $218.50, reflecting refined assumptions that include slightly higher revenue growth, a similar discount rate, modestly adjusted profit margins, and a small change in future P/E expectations, supported by broadly positive recent research across the diagnostic lab space. Analyst Commentary Street research around Quest Diagnostics has focused on how the company is positioned within the broader diagnostic lab group, with recent moves in peer guidance and a series of price target changes shaping sentiment on both upside potential and execution risk.Mise à jour du récit • Feb 21
DGX: Fair Outlook As Higher Payouts And Consumer Labs Support Future Earnings
Analysts have lifted their price target on Quest Diagnostics by about $18, reflecting slightly higher modeled revenue growth and a somewhat richer future P/E assumption, even as projected profit margins are trimmed in line with recent Street research that has broadly raised targets across the lab testing group. Analyst Commentary Bullish analysts have broadly raised their price targets on Quest Diagnostics, reflecting a more constructive view on the lab testing group as a whole and on Quest's positioning within it.Mise à jour du récit • Feb 06
DGX: Fair Outlook As Consumer Lab Partnerships And Margins Support Future Earnings
Analysts have inched up their fair value estimate for Quest Diagnostics to about $199 per share, a move they tie to slightly higher margin and P/E assumptions following recent research that points to potential upside to current earnings estimates. Analyst Commentary Recent Street research points to potential upside to current earnings estimates for Quest Diagnostics, which is feeding into a more constructive view on the stock’s valuation and execution risk.Mise à jour du récit • Jan 23
DGX: Future Consumer Lab Partnerships And Neurology Tests Will Support Balanced Outlook
Analysts have inched up their price target on Quest Diagnostics to about $198.38 from roughly $198.06, reflecting refreshed assumptions around slightly higher revenue growth, a small adjustment to profit margins, and a near steady forward P/E outlook. What's in the News Hims & Hers Health is offering lab testing that it views as a potential US$1b business, with customers accessing testing through Quest Diagnostics and then receiving results and care plans through the Hims platform (Wall Street Journal).Mise à jour du récit • Jan 06
DGX: Future Lab Partnerships And Testing Pipeline Will Support Bullish Outlook
Analysts lifted their price target for Quest Diagnostics by about US$1 to roughly US$198, citing recent Q3 results with sales and earnings ahead of consensus; raised full year guidance; firm organic volume trends; and growing interest in longer term opportunities, such as the Haystack MRD test and a generally supportive lab testing backdrop. Analyst Commentary Street research following the Q3 report points to a generally constructive tone, with multiple firms lifting their price targets and highlighting both execution on current fundamentals and potential longer term growth drivers.Mise à jour du récit • Dec 14
DGX: Future Lab Partnerships And Testing Pipeline Will Support Balanced Outlook
Analysts have nudged their price targets on Quest Diagnostics higher by between $5 and $25 per share, citing solid Q3 outperformance, raised guidance, and confidence in organic growth and future testing catalysts. Analyst Commentary Street research following the Q3 print highlights a generally constructive stance on Quest Diagnostics, with most price target increases framed around stronger than expected fundamentals and improving visibility into growth drivers over the next two years.Mise à jour du récit • Nov 29
DGX: Future Volume Gains And Lab Partnerships Will Support Balanced Outlook
The analyst price target for Quest Diagnostics was modestly increased to $197.31 from $197.25. Analysts cited stronger-than-expected earnings, raised guidance, and continued positive core trends as the rationale for the update.Mise à jour du récit • Nov 15
DGX: Future Revenue Expansion And Partnerships Will Balance Near-Term Risks
Quest Diagnostics saw its analyst price target increase, with several firms now projecting new targets between $195 and $215 per share. Analysts cite strong quarterly results and ongoing positive momentum in core business trends.Mise à jour du récit • Nov 01
DGX: Core Volume Momentum And New Blood Tests Will Drive Share Momentum
Quest Diagnostics' analyst fair value estimate has been raised from $191.56 to $197.25 per share. This change reflects analysts' upbeat outlook after strong quarterly results, improved profit margins, and continued momentum in core business trends.Mise à jour du récit • Oct 18
Preventive Diagnostics And Automation Will Shape Future Healthcare
Analysts have raised their fair value estimate for Quest Diagnostics from $188.19 to $191.56 per share, citing ongoing stable end markets and improving revenue growth expectations. Analyst Commentary Recent street research has highlighted a mix of optimism and caution surrounding Quest Diagnostics.Article d’analyse • Aug 20
Earnings Not Telling The Story For Quest Diagnostics Incorporated (NYSE:DGX)
Quest Diagnostics Incorporated's ( NYSE:DGX ) price-to-earnings (or "P/E") ratio of 21.6x might make it look like a...Analyse de la rémunération des PDG
| Date | Rémunération totale | Salaire | Bénéfices de l'entreprise |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | US$1b |
| Mar 31 2026 | n/a | n/a | US$1b |
| Dec 31 2025 | US$15m | US$1m | US$988m |
| Sep 30 2025 | n/a | n/a | US$963m |
| Jun 30 2025 | n/a | n/a | US$945m |
| Mar 31 2025 | n/a | n/a | US$892m |
| Dec 31 2024 | US$14m | US$1m | US$866m |
| Sep 30 2024 | n/a | n/a | US$838m |
| Jun 30 2024 | n/a | n/a | US$836m |
| Mar 31 2024 | n/a | n/a | US$842m |
| Dec 31 2023 | US$13m | US$1m | US$850m |
| Sep 30 2023 | n/a | n/a | US$759m |
| Jun 30 2023 | n/a | n/a | US$790m |
| Mar 31 2023 | n/a | n/a | US$789m |
| Dec 31 2022 | US$12m | US$806k | US$942m |
| Sep 30 2022 | n/a | n/a | US$1b |
| Jun 30 2022 | n/a | n/a | US$1b |
| Mar 31 2022 | n/a | n/a | US$2b |
| Dec 31 2021 | US$4m | US$625k | US$2b |
| Sep 30 2021 | n/a | n/a | US$2b |
| Jun 30 2021 | n/a | n/a | US$2b |
| Mar 31 2021 | n/a | n/a | US$2b |
| Dec 31 2020 | US$4m | US$577k | US$1b |
| Sep 30 2020 | n/a | n/a | US$1b |
| Jun 30 2020 | n/a | n/a | US$749m |
| Mar 31 2020 | n/a | n/a | US$771m |
| Dec 31 2019 | US$3m | US$590k | US$835m |
Rémunération vs marché: La rémunération totale de Jim ($USD 15.50M ) est dans la moyenne des entreprises de taille similaire sur le marché US ($USD 14.63M ).
Rémunération et revenus: La rémunération de Jim a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.
PDG
Jim Davis (63 yo)
3.7yrs
Titularisation
US$15,498,479
Compensation
Mr. James E. Davis, also known as Jim, serves as Chief Executive Officer and President at Quest Diagnostics Incorporated since November 1, 2022 and serves as its Director since November 2022 and Chairman o...
Équipe de direction
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| Chairman | 3.7yrs | US$15.50m | 0.12% $ 30.2m | |
| Executive VP & CFO | 4yrs | US$4.43m | 0.030% $ 7.6m | |
| Senior VP & General Counsel | 26.9yrs | US$2.56m | 0.035% $ 8.8m | |
| Executive Vice President of Regional Businesses | no data | US$3.56m | 0.059% $ 14.8m | |
| Senior Vice President of Clinical Solutions | 3.9yrs | US$2.58m | 0.014% $ 3.6m | |
| Senior VP | 7.3yrs | pas de données | 0.033% $ 8.2m | |
| Senior VP and Chief Information & Digital Officer | 2.2yrs | pas de données | pas de données | |
| Interim VP of Investor Relations & VP Finance | less than a year | pas de données | pas de données | |
| Senior VP & Chief Compliance Officer | 3.8yrs | pas de données | pas de données | |
| Senior VP and Chief Marketing & Communications Officer | no data | pas de données | pas de données | |
| Senior VP & Chief Human Resources Officer | 8.4yrs | pas de données | pas de données | |
| Senior Vice President of Diagnostic Services | 4.3yrs | US$2.15m | 0.014% $ 3.5m |
4.0yrs
Durée moyenne de l'emploi
61yo
Âge moyen
Gestion expérimentée: L'équipe de direction de DGX est considérée comme expérimentée (ancienneté moyenne 4 ans).
Membres du conseil d'administration
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| Chairman | 3.7yrs | US$15.50m | 0.12% $ 30.2m | |
| Independent Director | 12.5yrs | US$339.92k | 0.025% $ 6.3m | |
| Independent Director | 2.2yrs | US$324.92k | 0.0014% $ 342.0k | |
| Lead Independent Director | 14.6yrs | US$379.92k | pas de données | |
| Independent Director | 21.6yrs | US$349.92k | pas de données | |
| Independent Director | 7.4yrs | US$344.92k | 0.0060% $ 1.5m | |
| Director | less than a year | pas de données | pas de données | |
| Independent Director | 12yrs | US$344.92k | 0.017% $ 4.2m | |
| Independent Director | 6.3yrs | US$324.92k | 0.0014% $ 342.0k | |
| Independent Director | 4.9yrs | US$324.92k | pas de données | |
| Independent Director | 3.2yrs | US$324.92k | 0.0037% $ 923.0k |
6.3yrs
Durée moyenne de l'emploi
66yo
Âge moyen
Conseil d'administration expérimenté: Les membres du conseil d'administration de DGX sont considérés comme expérimentés (ancienneté moyenne 6.3 ans).
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/07/27 19:16 |
| Cours de l'action en fin de journée | 2026/07/24 00:00 |
| Les revenus | 2026/06/30 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github ; nous proposons également des guides sur la façon d’utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Quest Diagnostics Incorporated est couverte par 36 analystes. 16 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Jasper Hellweg | Argus Research Company |
| Eric Coldwell | Baird |
| Luke Sergott | Barclays |